A randomized trial of recombinant human soluble thrombomodulin (rhTM) among 800 adult patients with sepsis-associated coagulopathy failed to demonstrate a 28-day all-cause mortality among critically ill patients [30]. The gene discussed is THBD; the disease is blood coagulation disease.